Back | Next |
home / stock / rdgl / rdgl message board
Subject | By | Source | When |
---|---|---|---|
That's exactly how I would describe most of | lovethatgreen | investorshub | 07/02/2024 1:16:44 PM |
Chatgpt is only as good as the information | Truthsocial | investorshub | 07/02/2024 1:00:04 PM |
Power of ChatGPT. | AtlasQ | investorshub | 07/02/2024 12:31:20 PM |
Knew they were similar in targeted precision while | Bellionaire | investorshub | 07/02/2024 12:28:54 PM |
I gave you a follow you're at | lovethatgreen | investorshub | 07/02/2024 12:28:04 PM |
The Lilly buyout of Point Biopharma gives us | mikepgator | investorshub | 07/02/2024 12:11:03 PM |
### Comparison of Point Biopharma and Vivos Inc. | AtlasQ | investorshub | 07/02/2024 11:58:57 AM |
Wonder how their products compare to ours?🤔 | Bellionaire | investorshub | 07/02/2024 11:56:22 AM |
We will get there! | PioneerEmpire67 | investorshub | 07/02/2024 10:15:25 AM |
Disturbingly dumb yes I like that . I've | lovethatgreen | investorshub | 07/02/2024 9:37:34 AM |
MMs, feed me, Im hungry for more $RDGL | Rum_Tequila | investorshub | 07/02/2024 9:20:41 AM |
Only 60 million shares, and it's baked into | mc73 | investorshub | 07/02/2024 4:30:04 AM |
I'm noticing who sold or trimmed heavily and | lovethatgreen | investorshub | 07/02/2024 3:23:50 AM |
That detail needs to be ignored for now | lovethatgreen | investorshub | 07/02/2024 3:15:49 AM |
I get your POV WALLnut. However, speculations | WhAtEvA1 | investorshub | 07/02/2024 2:05:41 AM |
This news came later on Friday. We already | WALLnut | investorshub | 07/02/2024 1:51:31 AM |
Oh, I believe we'll hit bottom. Not worried | WALLnut | investorshub | 07/02/2024 1:47:51 AM |
Market is also factoring in 60 million new | mc73 | investorshub | 07/02/2024 1:38:56 AM |
Vivos is treating cancer successfully. We should be | WALLnut | investorshub | 07/02/2024 1:35:13 AM |
WALLnut, you are the most realistic on here. | PioneerEmpire67 | investorshub | 07/02/2024 1:33:31 AM |
News, Short Squeeze, Breakout and More Instantly...
--News Direct-- By Meg Flippin, Benzinga In what could prove to be a transformational development in cancer treatment, Vivos (OTCQB: RDGL), the maker of the Radiogel™ Precision Radionuclide Therapy, submitted an application to the U.S. Food and Drug Administration (FDA) to init...
Richland WA, June 28, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. filed the application for an Investigational Device Exemption (“IDE”). The filing was an amendment, addressing the FDA comments to our previous application (Q211938/S001). Today’...
Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31 Hongchang International Co Ltd Com (New) (HCIL) is expected to report for Q4 2023 BioStem Technologies Inc (BSEM) is expected to report $0.47 for Q4 2023 Nicox SA (NICXF) is expected to report $-0.07 for Q4 2023 ...